<DOC>
	<DOCNO>NCT00060086</DOCNO>
	<brief_summary>RATIONALE : Pomegranate juice may contain substance decrease slow rise prostate-specific antigen ( PSA ) level may effective delay prevent recurrent prostate cancer . PURPOSE : This phase II trial study well pomegranate juice work decrease slow rise PSA level patient undergone radiation therapy surgery prostate cancer .</brief_summary>
	<brief_title>Pomegranate Juice Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether pomegranate juice decrease slow rise prostate-specific antigen ( PSA ) level patient undergone radical prostatectomy radiotherapy adenocarcinoma prostate . OUTLINE : Patients receive oral pomegranate juice daily . Treatment continue 18 month absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 29-40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Must undergone prior surgery radiotherapy primary tumor Documented rise prostatespecific antigen ( PSA ) level , define follow criterion : Absolute level PSA least 0.2 ng/mL less 5.0 ng/mL Rising PSA level must confirm least 1 week later Adequate PSA time point calculate PSA double time Gleason score great 7 Age 18 Performance status ECOG 01 Life expectancy least 6 month No malignancy within past 5 year except nonmelanoma skin cancer No serious concurrent systemic medical disorder would preclude study compliance No known allergy pomegranate juice More 4 week since prior participation another experimental study nodal involvement evidence metastatic disease prior hormonal therapy concurrent hormonal therapy rise PSA level initial therapy prostate cancer concurrent participation another experimental study concurrent systemic local therapy prostate cancer initiation discontinuation new nutritional dietary supplement study participation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>